An increased nuchal translucency and a family history of severe intellectual disability do not create one universal “best genetic test.” They create two separate clinical questions: Is the fetus at increased risk for aneuploidy or structural disease, and did the fetus inherit an unstable maternal FMR1 allele?
Consider a 31-year-old primigravid patient at 11 weeks. Her younger brother has severe intellectual disability, autism spectrum disorder, and lifelong care needs; the family recalls prominent ears and a prominent jaw but has no molecular diagnosis. Her ultrasound shows a crown–rump length of 45 mm and an NT of 3.2 mm. Maternal testing identifies 80 CGG repeats on one FMR1 allele. She wants a definitive answer but fears procedure-related pregnancy loss.
The high-yield move is not to choose between cfDNA and invasive testing before defining the question. It is to separate the risk streams and then select a test for each one.
Start with the pedigree, not the facial description
The brother’s phenotype is suggestive of an FMR1-related disorder, but it is not diagnostic. Prominent ears, a long or prominent jaw, autism, and intellectual disability can occur in Fragile X syndrome, yet many affected individuals lack a recognizable facial phenotype, and many other genetic conditions produce a similar presentation.
Clarify whether the brother ever had FMR1 testing, chromosomal microarray, exome or genome sequencing, or another genetic evaluation. A result from the affected relative can convert a suggestive family history into a defined familial diagnosis. It also prevents the common error of assuming that every familial intellectual disability is Fragile X.
The pedigree should include more than intellectual disability. Ask about unexplained autism, learning disability, premature ovarian insufficiency or early menopause, and tremor or ataxia in older maternal relatives. Those findings can support an FMR1-related family pattern, but their absence does not exclude it.
| Case clue | What it should trigger | What it does not prove |
|---|---|---|
| Brother with severe intellectual disability and autism | Review records and offer targeted FMR1 assessment | That the brother has Fragile X syndrome |
| Maternal allele with 80 CGG repeats | Counseling about an FMR1 premutation and fetal diagnostic options | That the fetus is affected |
| NT of 3.2 mm | Evaluation for aneuploidy, structural disease, and selected genetic syndromes | That the fetus has trisomy 21 or Fragile X |
An 80-repeat result is a premutation, not an affected fetus
An FMR1 allele with 80 CGG repeats is in the premutation range, generally defined as 55–200 repeats. A full-mutation allele is generally greater than 200 repeats and, in most cases, is hypermethylated, which reduces or silences FMR1 expression.
The premutation matters because a maternal allele can expand during transmission. However, an 80-repeat result does not translate into a single fixed fetal risk. The number of repeats is important, but AGG interruptions within the CGG tract and family-specific transmission history can materially change the estimated probability of expansion to a full mutation. Laboratory method and repeat-sizing precision can also affect how the allele is classified and how risk estimates are applied. When available, AGG interruption analysis can refine counseling, especially for alleles below 100 repeats.
The patient herself is not being diagnosed with classic Fragile X syndrome by this result. Female premutation carriers may have increased risks for Fragile X-associated primary ovarian insufficiency and Fragile X-associated tremor/ataxia syndrome, but those are separate counseling issues from the current fetal diagnosis.
Each pregnancy has a 50% chance of inheriting the maternal X chromosome carrying the premutation; that allele may remain in the premutation range or expand during transmission. That is not the same as a 50% chance of classic Fragile X syndrome. The inherited allele may remain in the premutation range or expand to a full mutation. If a full mutation is present, males are often more severely affected, while females have a broad range of expression influenced in part by X-inactivation. Sex can modify phenotype; it does not make the result predictable.
Pick the test by the question
| Clinical question | Useful test | Important limitation |
|---|---|---|
| Does the mother carry an unstable FMR1 allele? | Maternal FMR1 CGG-repeat analysis, with AGG analysis when available | It describes the mother’s allele, not the fetus’s inherited repeat size |
| Is the fetus at increased risk for trisomy 21, 18, or 13? | cfDNA screening or invasive chromosome testing | cfDNA is a screening test and does not assess FMR1 repeat expansion |
| Did the fetus inherit a maternal premutation or full mutation? | CVS or amniocentesis with targeted fetal FMR1 testing | The result addresses FMR1 status, not every genetic or structural condition |
| Could the increased NT reflect a chromosomal or structural disorder? | Diagnostic chromosome testing when chosen, followed by detailed ultrasound assessment | No single test excludes all structural or molecular diagnoses |
This is the central counseling distinction: maternal carrier screening is not fetal diagnosis, and cfDNA screening for common aneuploidies is not an FMR1 test. A negative cfDNA result could lower the probability of the common trisomies, but it would not answer whether the fetus inherited the maternal premutation or whether it expanded.
A normal karyotype or chromosomal microarray also does not reliably exclude an FMR1 repeat expansion. The laboratory must receive a specific request for targeted FMR1 analysis.
CVS or amniocentesis at 11 weeks?
Because the patient is 11 weeks pregnant and wants an early definitive answer, CVS is a reasonable option to discuss. CVS is usually performed between 10 and 13 weeks and samples placental tissue. Amniocentesis is generally performed from 15 weeks onward and analyzes fetal cells in amniotic fluid.
For a known maternal premutation carrier, prenatal diagnosis should be offered. CVS can determine the fetal repeat size, but interpretation has an important caveat: methylation of a full-mutation allele may not yet be fully established in chorionic villi, particularly early in gestation. If CVS identifies a full mutation or produces an ambiguous result, the laboratory or genetics team may recommend follow-up amniocentesis to clarify the fetal result or methylation status. Methylation status should not be used by itself to predict clinical severity.
Amniocentesis provides a later fetal sample and may avoid that particular placental-methylation limitation, but the result arrives later. Both procedures carry a small procedure-related pregnancy-loss risk. The number quoted during consent should reflect current local data, operator experience, and the patient’s specific circumstances rather than an outdated universal percentage.
The decision should be tied to what the patient would do with the information. If an early result would change pregnancy management, preparation, or the timing of additional counseling, CVS may fit her priorities. If she strongly prefers to wait for amniocentesis and is comfortable with a later answer, that is also a reasonable choice. Declining invasive testing after informed counseling remains an option.
Run the NT evaluation in parallel
An NT of 3.2 mm at a CRL of 45 mm should be reviewed as an increased-NT finding according to the local reference standard and measurement quality. It is a risk marker, not a diagnosis. The differential includes common aneuploidies, cardiac and other structural abnormalities, and selected single-gene syndromes such as RASopathies.
The increased NT does not explain the brother’s history, and the family history does not explain away the NT. If the patient chooses invasive testing, the genetics and laboratory teams should plan both components in advance: targeted FMR1 testing for the familial risk and appropriate chromosome analysis, with microarray considered according to the ultrasound findings and counseling plan.
Regardless of the screening choice, arrange comprehensive second-trimester anatomy imaging, typically at 18–22 weeks. A targeted fetal cardiac assessment may also be considered based on the NT measurement, later imaging, and local maternal-fetal medicine protocol. A normal early result cannot replace that structural evaluation.
Common traps in this case
- Treating the brother’s appearance as a diagnosis: phenotype raises suspicion; molecular testing establishes the familial disorder.
- Calling 80 repeats a full mutation: 80 repeats indicates a premutation, not classic Fragile X syndrome in the mother or an affected fetus.
- Using a fixed expansion percentage: repeat count alone is incomplete; AGG structure and family context matter.
- Using negative cfDNA as reassurance about Fragile X: cfDNA for common aneuploidies does not answer the FMR1 question.
- Calling NT 3.2 mm “Down syndrome”: NT increases risk and broadens the differential; it does not identify the cause.
- Assuming one normal microarray ends the work-up: targeted repeat-expansion testing is still required when FMR1 risk is present.
- Choosing CVS or amniocentesis without discussing the result’s purpose: diagnostic testing is most useful when the patient understands what it can answer, what it cannot answer, and how the result would affect her decisions.
Practical takeaways
- Separate the familial FMR1 question from the ultrasound-based aneuploidy and structural-risk question.
- An 80-CGG-repeat maternal allele is a premutation; it creates a meaningful expansion risk but does not diagnose the fetus.
- The simple 50% inheritance figure refers to transmission of the maternal premutation-containing X chromosome, not automatically to classic Fragile X syndrome.
- cfDNA can screen for common aneuploidies but cannot replace fetal FMR1 diagnosis.
- At 11 weeks, CVS offers earlier fetal testing; amniocentesis offers later testing, with different interpretive and timing considerations.
- An increased NT deserves its own diagnostic and ultrasound pathway, even when the family history already suggests a genetic condition.
